FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Autologous hematopoietic stem cell transplantation in pediatric multiple sclerosis: Long-time follow-up: STUDY

















Image source: SCLERODERMANEWS

Abstract

Objective:
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is the method of choice for patients with refractory multiple sclerosis (MS). We have studied the effectiveness and long-time results of this method in pediatric patients.

Methods:
10 patients were included into the study: 8 females, 2 males. Median age was 16.7±1.7. Median MS duration prior to Auto-HSCT was 15.5±4.1. Age of MS onset: 4–14 years of age (12.3±1.7). Initial median score on the Expanded Disability Status Scale (EDSS) was 6.16±0.2. All patients had severe refractory MS treated with corticosteroids, interferons, plasmapheresis and mitoxantron with negative results. All patients had inflammation signs. Procedures included: stem cells mobilization with Cyclophosphomide, conditioning with Cyclophosphomide 200 mg/kg and ATGAM 160 mg/kg. Median follow-up was 21.1±0.9 (4–60 months).

Results:
All patients demonstrated positive results with EDSS improvement: from 2.5±0.21 in the first 60 days to 0.2±0.02 after 60 days. Maximal individual EDSS improvement was 5.5. EDSS at 2 patients improved to 1. Five patients had severe refractory secondary-progressive MS with the long duration of ineffective treatment. These patients showed the minor improvement and required the additional immunomodulation after Auto-HSCT. 2 patients relapsed (on clinical and MRI data). No severe complications were registered.

Conclusion:
Auto-HSCT is an effective approach to autoimmune inflammation reduction and treatment of severe refractory pediatric MS. In-time Auto-HSCT can significantly minimize the disability level and improve the outcome of MS. Most patients remained in remission during the long period.

Story Source: The above story is based on materials provided by EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY
Note: Materials may be edited for content and length
Click here to read original article

Labels: , ,



Go to Newer News Go to Older News